Creating a new method for editing DNA in mammalian cells without CRISPR
Official title: Developing a CRISPR-free mammalian recombineering system
Funded at Scripps Research Institute, the · NIH-10910639 · Data updated 2026-11-12
This study is exploring a new way to change DNA in human cells safely and accurately, which could lead to better gene therapies and treatments for genetic disorders.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $1,638,033 |
| NIH project number | 1DP2GM159183-01 |
| Project ID | NIH-10910639 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with genetic disorders that could potentially be treated through advanced gene editing techniques.
✕Less likely to help
Patients with conditions that do not involve genetic alterations or those who are not candidates for gene therapy may not benefit from this research.
What this research studies
This research focuses on developing a novel system for manipulating large segments of DNA in mammalian cells without the use of CRISPR technology. The approach aims to enable precise insertions, deletions, and substitutions of DNA without causing harmful double-strand breaks. By utilizing bacterial recombinases, the researchers will optimize this system to enhance its efficiency and effectiveness for various genetic modifications. Patients may benefit from advancements in gene therapy and treatments for genetic disorders as a result of this innovative technology.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective gene therapies for patients with genetic disorders.
How similar studies have gone: While CRISPR has been widely studied and applied, this approach using bacterial recombinases represents a novel and untested method in mammalian cells.
Where this research is happening
-
Scripps Research Institute, the
La Jolla, United States Active
Researchers
- Principal investigator: Miller, Shannon Marie — Scripps Research Institute, the
- Study coordinator: Miller, Shannon Marie
Related research
Other NIH-funded projects on the same topics.
-
The Participant Center helps people join and stay in a nationwide health study
A nationwide program to support people in joining, contributing biosamples, and staying connected to a large health study in the United States.
-
Data Sharing and Bioinformatics Core for Viral Systems Biology
A center-led effort to manage, share, and interpret large viral systems biology data using open tools and a community-friendly portal.
-
Germline-targeted HIV vaccines using membrane liposome tech to trigger bnAbs
A new HIV vaccine approach aims to spark broadly neutralizing antibodies by showing MPER on membranes, tested in models and early studies to guide future human trials.
-
Antivirals for hemorrhagic fever viruses like LASV, SFTSV, and EBOV
A multi-institutional effort to find and validate antiviral compounds that block key viral proteins from LASV, SFTSV, and EBOV to help people at risk from serious hemorrhagic fevers.
-
Developing new antivirals for flaviviruses
A research team is working to create oral antiviral drugs targeting flaviviruses to treat infections that affect millions of people.
-
CoV inhibitors targeting non-enzymatic SARS-CoV-2 components
A multicenter research effort seeks antiviral ideas that block SARS-CoV-2 parts that don’t work through traditional enzymes, aiming to help people affected by COVID-19.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.